Eris Lifesciences Limited
Franklin Templeton Mutual Fund increased its stake in Eris Lifesciences from 4.06% to 4.29%, buying 329,077 shares. In July, Franklin Templeton Mutual Fund had bought 10.94 lakh shares of Eris Lifesciences for ₹109.42 crore at ₹1,000.04 apiece.
A pharmaceutical manufacturer and marketer, ERIS Lifesciences produces branded and generic drugs across multiple therapeutic areas including cardiovascular, gastroenterology, and anti-infective segments. The company operates manufacturing facilities and distributes medications through established distribution networks to serve both domestic and international markets. It focuses on developing and delivering cost-effective pharmaceutical formulations for diverse patient populations.
Indian arm of Franklin Templeton Investments, a global AMC with over USD 1.5 trillion in assets worldwide. Manages over Rs 1.2 lakh crore in India. Navigated a significant setback when six debt schemes were wound up in April 2020 due to illiquid credit exposure, with full investor capital recovered by 2022. Equity franchise led by CIO Anand Radhakrishnan has maintained consistent performance through the volatility.